Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics CFO Constance Ames resigns; Stephanie Horn-Warnock named CFO

Neutral Impact 4 of 5 leadership Written later

Tempest Therapeutics said Chief Financial Officer Constance Ames resigned effective immediately on October 26, 2026, citing personal considerations unrelated to the company. The board appointed Stephanie Horn-Warnock as CFO, principal financial and accounting officer, treasurer and corporate secretary, also effective immediately, and she will work for the company as a consultant under an engagement letter dated October 28, 2026.

Key points

  • Constance Ames resigned as CFO and from all other company positions, effective immediately, for personal considerations unrelated to the company.
  • Stephanie Horn-Warnock, 37, was appointed CFO effective immediately on October 26, 2026.
  • Horn-Warnock previously was Vice President of Finance at ROM Technologies Inc. from January 2024 to September 2026.
  • Under her consulting engagement letter dated October 28, 2026, the company will pay $450 per hour plus expenses and an indirect cost allocation of 5.0% of total professional fees.

The filing

CompanyTempest Therapeutics, Inc. (TPST)
Form8-K, current report
Filed with the SECOct 30, 2026, 4:05 PM ET
Accession number0001213900-26-114376

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.